Abstract
The objectives of this study are to assess the role of non-chemotherapeutic combination of drugs as maintenance therapy, after standard treatment, for advanced epithelial ovarian cancers (EOC) and to determine the recurrence-free survival (RFS) and cancer-specific survival (CSS). One hundred women with advanced high-grade EOC who had completed standard treatment by primary/interval debulking surgery followed by adjuvant chemotherapy were randomised to either receive (study group) or not to receive (control group) the non-chemotherapeutic maintenance therapy (oral metformin, anastrozole, aspirin, atorvastatin, vitamin D, injection zoledronic acid). Both groups were followed up, and trends of RFS and CSS were analysed. One hundred patients were analysed. Median RFS was 18 months (95% CI: 13–24) in study group versus 16 (95% CI: 14–20) in the control group (P value = 0.57). Median CSS in the study group was lesser than that in the control group (47 months (95% CI: 31–68) versus 51 (95% CI: 32–66), P value = 0.76). Five-year CSS was not significantly different between the groups (47% study vs 40% control, P value = 0.51). The use of combination of non-chemotherapeutic drugs as maintenance therapy was found to have no significant impact on the survival or reduction of recurrences in patients with advanced epithelial ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Available upon reasonable request.
References
Brey F et al (2018) Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
Kobayashi Y, Banno K, Kunitomi H, Tominaga E, Aoki D (2019) Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. J Gynecol Oncol 30(1):e10
Dalton et al (2014) Bisphosphonates: new strategies for targeting angiogenesis in ovarian cancer. Cancer Res 74(19 Supplement):2983
Wield AM, Walsh CS, Rimel BJ, Cass I, Karlan BY, Li AJ (2018) Aspirin use correlates with survival in women with clear cell ovarian cancer. Gynecol Oncol Rep 25:78–81
Guo H, Guo J, Xie W, Yuan L, Sheng X (2018) The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention. J Ovarian Res 11(1):71
Foster R, Buckanovich RJ, Rueda BR (2013) Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett 338(1):147–157
Ahmed N, Abubaker K, Findlay JK (2014) Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets. Mol Asp Med 39:110–125
Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, Watanabe K, Iijima M, Takeda T, Kunitomi H, Iida M, Adachi M, Nakamura K, Tsuji K, Masuda K, Nomura H, Tominaga E, Aoki D (2017) Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget. 8(42):72147–72156
Shi J, Liu B, Wang H, Zhang T, Yang L (2019) Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis. Int J Gynecol Cancer 29(1):140–146
Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W, Shridhar V (2013) Metformin intake is associated with better survival in ovarian cancer: a case-control study. Obstet Gynecol Surv 68(4):293–294
Romero IL, McCormick A, McEwen KA et al (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119(1):61–67
Wang SB, Lei KJ, Liu JP, Jia YM (2017) Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: a retrospective study. Medicine (Baltimore) 96(29):e7605
Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9):3196–3201
Hamedi B, Khalili A, Roozmeh S, Namazi G, Saraf Z (2018) Combination of metformin and chemotherapy decreases the recurrence rates of epithelial ovarian cancers: a randomized clinical trial. Int J Cancer Manag 11(7):e11621
Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Hinkula M, Läärä E (2018) Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer 18(1):767
Verdoodt F, Kjaer Hansen M, Kjaer SK, Pottegard A, Friis S, Dehlendorff C (2017) Statin use and mortality among ovarian cancer patients: a population-based cohort study. Int J Cancer 14(2):279–286
Knipprath-Mészáros AM, Vetter M, Montavon C, Vigo F, Schoetzau A, Heinzelmann-Schwarz VA (2017) Aromatase inhibitor maintenance therapy in high grade advanced ovarian cancer to delay first recurrence. J Clin Oncol 35(15_suppl):5515–5515
Heinzelmann-Scwarz et al (2018) Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. GynecolOncol. 148(1):79–85
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no conflict of interest.
Patient Consent
Patient consent was obtained.
Disclaimer
The content of this paper reflects the opinion of the authors.
Code Availability
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 15 kb)
Rights and permissions
About this article
Cite this article
Shivdas, S., Rajatharangani, T., Rathod, P.S. et al. A Prospective Study on Metronomic Scheduling of Non-chemotherapeutic Drugs in Advanced Epithelial Ovarian Cancers. Indian J Surg Oncol 12, 127–132 (2021). https://doi.org/10.1007/s13193-020-01261-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-020-01261-w